[Trastuzumab emtansine for breast cancer]

Itkin B, Gonzalez L, Pichon-Riviere A, Augustovski F, García Martí S, Alcaraz A, Bardach A, Ciapponi A.
Record ID 32018001478
Original Title: Trastuzumab emtansina en cáncer de mama
Authors' recomendations: CONCLUSIONS High-quality evidence shows that trastuzumab emtansine (T-DM1) use in patients with advanced HER2+ breast cancer patients, previously treated with trastuzumab and a taxane, improves overall survival, progression-free survival and the quality of life with a lower incidence of serious adverse effects when compared with lapatinib and capacitabine use or other antineoplastic therapies. Most health sponsors from high-income countries, as well as several public health sponsors in Latin America consulted, cover the drug for this group of patients. Some sponsors from high-income countries report that this technology is not cost-effective at the suggested price, demanding a price reduction as a pre-requisite. Moderate-quality evidence suggests that in patients with advanced disease who did not receive prior treatment, T-DM1 alone or in combination with pertuzumab, is not superior to the combination of trastuzumab plus a taxane. This regimen proved to be less effective than the preferred one currently used for this group of patients: docetaxel, trastuzumab plus pertuzumab. Moderate-quality evidence suggests that in patients with Stage II and III breast cancer, T-DM1 in combination with pertuzumab as neoadjuvant treatment is less effective than carboplatin, docetaxel, trastuzumab plus pertuzumab. T-DM1 use in the latter two groups of patients is not authorized by the main regulatory agencies or recommended by the clinical practice guidelines or considered by the sponsors assessed.
Project Status: Completed
Year Published: 2018
URL for published report: https://www.iecs.org.ar/home-ets/
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Argentina
MeSH Terms
  • Breast Neoplasms
  • Trastuzumab
  • Ado-Trastuzumab Emtansine
  • Antineoplastic Agents, Immunological
Organisation Name: Institute for Clinical Effectiveness and Health Policy
Contact Address: Dr. Emilio Ravignani 2024, Buenos Aires - Argentina, C1414 CABA
Contact Name: info@iecs.org.ar
Contact Email: info@iecs.org.ar
Copyright: Institute for Clinical Effectiveness and Health Policy (IECS)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.